Two first-line combination treatments for newly diagnosed type 2 diabetes
Comparative Effectiveness of Two Initial Combination Therapies in Patients with New Onset Diabetes
This compares whether starting two diabetes medicines together helps people newly diagnosed with type 2 diabetes keep their blood sugar under control longer than the usual step-by-step approach.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Science Center NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project ID | NIH-11291307 on NIH RePORTER |
What this research studies
If you join, you'll be randomly assigned to one of two initial two-drug treatment combinations and followed over time. The study team will check your blood sugar (HbA1c), weight, side effects, and measures of insulin/beta-cell function at regular clinic visits. Researchers will track how long each treatment keeps HbA1c below the target and note other outcomes like body fat and bone measures. Visits may include blood draws, exams, and questionnaires over several years.
Who could benefit from this research
Good fit: Ideal candidates are adults recently diagnosed with type 2 diabetes who are not yet on complex diabetes regimens and do not have significant heart or kidney disease.
Not a fit: People with long-standing diabetes, type 1 diabetes, advanced cardiovascular or renal disease, or who cannot attend clinic visits are unlikely to benefit from joining this effort.
Why it matters
Potential benefit: If successful, this could help people with new type 2 diabetes keep blood sugar under control longer and delay the need for more medications or diabetes complications.
How similar studies have performed: Earlier trials like VERIFY and EDICT showed that some initial two-drug combinations can delay blood-sugar failure compared with adding drugs later, but many patients still lost control over five years, so results are promising but not definitive.
Where this research is happening
San Antonio, United States
- University of Texas Hlth Science Center — San Antonio, United States (Active)
Researchers
- Principal investigator: Abdul-Ghani, Muhammad — University of Texas Hlth Science Center
- Study coordinator: Abdul-Ghani, Muhammad
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.